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Highlights 
 
PARP-1 is not a key regulator of photochemotherapy. 
The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP 
independent mechanism.  
Photosensitization by PJ-34 is associated with increased ROS production and DNA damage. 
Cells sensitized by PJ-34 undergo caspase-mediated apoptosis. 
 
Abstract 
A combination of a photosensitizer with light of matching wavelength is a common treatment 
modality in various diseases including psoriasis, atopic dermatitis and tumors. DNA damage 
and production of reactive oxygen intermediates may impact pathological cellular functions 
and viability. Here we set out to investigate the role of the nuclear DNA nick sensor enzyme 
poly(ADP-ribose) polymerase 1 in photochemical treatment (PCT)-induced tumor cell killing. 
We found that silencing PARP-1 or inhibition of its enzymatic activity with Veliparib had no 
significant effect on the viability of A431 cells exposed to 8-methoxypsoralen (8-MOP) and 
UVA (2.5 J/cm2) indicating that PARP-1 is not likely to be a key player in either cell survival or 
cell death of PCT-exposed cells. Interestingly, however, another commonly used PARP 
inhibitor PJ-34 proved to be a photosensitizer with potency equal to 8-MOP. Irradiation of PJ-
34 with UVA caused changes both in the UV absorption and in the 1H NMR spectra of the 
compound with the latter suggesting UVA-induced formation of tautomeric forms of the 
compound. Characterization of the photosensitizing effect revealed that PJ-34+UVA triggers 
overproduction of reactive oxygen species, induces DNA damage, activation of caspase 3 and 
caspase 8 and internucleosomal DNA fragmentation. Cell death in this model could not be 
prevented by antioxidants (ascorbic acid, trolox, glutathione, gallotannin or cell permeable 
superoxide dismutase or catalase) but could be suppressed by inhibitors of caspase-3 and -8. 
In conclusion, PJ-34 is a photosensitizer and PJ-34+UVA causes DNA damage and caspase-
mediated cell death independently of PARP-1 inhibition.  
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Introduction 
Phototherapy, photochemotherapy and photodynamic therapy are efficient treatment 
modalities used to treat various different types of diseases ranging from psoriasis [1], acne [2] 
to certain forms of cancer [3] [4] [5]. 
Photodynamic therapy (PDT) is based on the combination of a photosensitizing compound 
with irradiation using a light source emitting at or near the absorption maximum of the 
photosensitizer [6]. In turn, the excited photosensitizer promotes the generation of oxygen 
radicals by directly (type I reaction) or indirectly (via intracellular substrates; type II reactions) 
interacting with molecular oxygen [7]. Reactive oxygen species (ROS) formed in these 
reactions mediate the cytotoxic effects of PDT [8].  
Photochemotherapy (PCT) utilizes the combination of psoralen with suberythemogenic 
ultraviolet A (PUVA) [9]. Psoralens are tricyclic furocoumarins [10] with 5- methoxypsoralen (5-
MOP), 8-methoxypsoralen (8-MOP) and trioxalen (TMP) being the most commonly used 
sensitizers [11]. Photochemical interaction between psoralens and DNA may follow three 
pathways: a) intercalation of psoralen into DNA (it may also take place without UV radiation); 
b) formation of 3,4-monoadducts or 4,6-monoadducts with the latter being capable of 
crosslinking psoralen with DNA following the absorption of a second photon; c) excited 
psoralen may directly react with molecular oxygen leading to the generation of singlet oxygen 
as in PDT [12]. 
PCT or PDT trigger DNA damage either directly or via ROS generation [13] [14]. The 
cellular response to DNA strand breaks caused by ROS or by the nucleotide excision repair 
pathway involves the activation of poly(ADP-ribose) polymerase-1 (PARP-1). PARP-1 is a 
DNA nick sensor enzyme that is abundantly expressed by most eukaryotic cell types [15] [16] 
[17]. Upon binding to broken DNA ends, PARP-1 becomes activated and modifies itself and 
nearby proteins with NAD-derived ADP-ribose. By cleaving more NAD molecules and 
attaching their ADP-ribose moieties to the protein proximal ADP-ribose unit, PARP-1 creates 
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a long, branched poly(ADP-ribose) (PAR) polymer that is essential for the recruitment of 
various adapter and effector DNA repair proteins [18]. 
From its role in DNA repair follows the plausible assumption that PARP-1 can be 
considered as a “survival enzyme”. Indeed, inhibition of its activity (or silencing of its 
expression) sensitizes cells (e.g., cancer cell lines) to subtoxic doses of ionizing radiation [19], 
DNA alkylating agents [20] or topoisomerase [21] inhibitors. In fact, the clinical value of such 
sensitization therapy has been tested in various promising clinical trials suggesting that certain 
tumors can indeed be eradicated more efficiently if DNA damaging chemotherapeutics are 
combined with PARP inhibitors [22] [23]. It may be worth mentioning here that PARP-1 
inhibition/silencing/knockout may also protect cells from programmed necroptotic cell death 
(e.g., under conditions of severe oxidative stress) [24]. Thus, depending on the intensity of the 
genotoxic stimulus PARP-1 may act as a dual regulator of cell fates [16]. 
In a previous study from our group we reported a surprising photosensitizing effect of the 
PARP inhibitor PJ-34 in UVA-irradiated keratinocytes [25]. This has prompted us to investigate 
whether PARylation represents a possible target in PCT and whether efficiency of PCT can be 
improved by targeting PARP-1. It appears that while targeting PARP-1 is not likely to enhance 
the efficiency of PCT, one of its most widely used inhibitor PJ-34 sensitizes tumor cells to the 
toxic effects of UVA. Interestingly, however, the photosensitizing effect of PJ-34 is unrelated 
to its PARP inhibitory property.  
 
1. Materials and Methods 
1.1. Cell culture 
The human epidermoid carcinoma cell line A431 (European Collection of Cell Cultures) 
was cultured in Dulbecco’s modified Eagle’s medium with high glucose supplemented with 
10% heat-inactivated fetal bovine serum (Sigma- Aldrich, St. Louis, MO), 5% penicillin-
streptomycin and 5%, L-glutamine (Lonza, Basel, Switzerland). Cells were maintained at 37°C 
in a humidified atmosphere (5% CO2), and were split at 70-80% confluency after trypsinization 
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with trypsin-EDTA solution (Sigma- Aldrich, St. Louis, MO). Cultures at 80-95% confluency 
were used in all experiments. 
 
1.2. Spheroid culture 
     We grew spheroids from A431 cells in 96 well plates pre-coated with 0.5% agar-water 
solution. Cells were seeded onto plates at 1x104 cells/ml density in 50 µl cell suspension per 
well. The cells were allowed to clump together for 48 h and were then pretreated with PARP 
inhibitors (PJ-34 and Veliparib) for 50 min. Cells were irradiated with UVA (2.5 J/cm2) as 
described below. Immediately after irradiation, the medium was changed to fresh cell culture 
medium and spheroids were incubated for 16 h. Pictures of spheroids were taken with a Leica 
confocal microscope system. Diameter of spheroids was measured with Image J software. 
 
1.3. Cell treatment and UVA irradiation 
In all experiments the cells were pretreated for 50 min with the photosensitizer 0.8 M 8-
methoxypsoralen (8-MOP) or with PARP inhibitors, 10 μM PJ-34 (Inotek Corporation, Beverly, 
MA) or 10 μM Veliparib (Selleck Chemicals, Munich, Germany). In assays involving 
antioxidants, 200 μM Trolox (Sigma- Aldrich, St. Louis, MO) or 500 μM ascorbic acid (Sigma- 
Aldrich, St. Louis, MO) were added to the cultures together with the PARP inhibitors. Following 
pretreatment the cells were irradiated with UVA (2.5 -10 J/cm2) in the presence or absence of 
PARP inhibitors in plates of uniform depth (0.109 cm in 96 well plate and 24 well plate) of 
phosphate-buffered saline (PBS) (0.2 M, pH 7.4). The cells were irradiated with a Bio-Sun 
microprocessor-controlled UV irradiation system (Wilber Lourmat, Marne-la-Vallée, France). 
The equipment operates at wavelength 365 nm (UVA): After irradiation PBS was replaced with 
fresh cell culture medium.  
 
1.4. Cell viability assay 
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Cell viability was determined with MTT assay at indicated time points after irradiation [26]. 
 
1.5. Detection of reactive oxygen species 
A431 cells were seeded into 96 well plates one day before the experiments. Cells were 
incubated for 50 min with 10 µM 2’,7’-dichlorodihydrofluorescein diacetate (Sigma-Aldrich, St. 
Louis, MO), (In preliminary experiments we have established that in a cell-free system UVA 
irradiation does not activate H2DCFDA and increased fluorescence could not be detected in 
UVA-irradiated H2DCFDA solution.). Fluorescence was detected with a Fluoroskan Ascent FL 
plate reader (Thermo Scientific, Vantaa, Finland) immediately after UVA irradiation (ex. 480 
nm, em. 590 nm). 
 
1.6. Gene silencing 
A431 cells were transfected in suspension (after trypsinization and prior to seeding). 
SiGENOME SMARTpool siRNA specific for human PARP-1 sequence, ON-TARGET plus 
Control siRNA and DharmaFECT 2 transfection reagent were obtained from Dharmacon 
Research, Inc. (Lafayette, CO) and silencing was carried out according to the manufacturer’s 
instruction. After 48 h, efficiency of silencing was determined from 24-well plates by Western 
blotting and cells in 96-well plates were used for the viability assay 16 h after irradiation with 
different doses of UVA (2.5-10 J/cm2). 
 
1.7. Western-blotting 
Antigens were detected by Western blotting according to standard procedures as described 
previously [27]. Antibodies specific for PAR (primary antibody: clone 10H), PARP-1, 
H2AX/gamma-H2AX, cleaved-PARP-1 were purchased from Cell Signaling Technology Inc. 
(Danvers, MA)  
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1.8. Immunostaining for -H2AX 
Cells were irradiated with 5 J/cm2 UVA for 30 min, then fixed (4% PFA for 20 min) and 
permeabilized (0.2% Triton X-100 in PBS buffer for 15 min). After washing, cells were 
blocked for one hour with 20% FCS in PBS buffer. Labeling with anti--H2.AX antibody 
(Cell Signaling Technology, Danvers, MA) was performed overnight at 4oC. Samples 
were washed three times with PBS and then incubated for 45 min with the peroxidase-
conjugated secondary antibody (Envision, Dako). Color was developed with the 
chromogen DAB (3,3'-diaminobenzidine) substrate. After mounting, samples were 
viewed and imaged with a LeicaTCS SP8 confocal microscope. Foci were evaluated 
in Image J with Focinator extension [28]. 
 
1.9. Comet assay 
Single-stranded DNA breaks were detected by alkaline comet assay (single-cell gel 
electrophoresis) as described previously [29]. 
 
1.10. Caspase activity assay and DNA fragmentation 
Cells were harvested 4, 8, 16 h after irradiation, washed 1x with PBS and were lysed in lysis 
buffer [10 mM HEPES, 0,1% CHAPS, 5 mM dithiothreitol, 2 mM EDTA, 1 mM proteinase-
inhibitor cocktail (Sigma-Aldrich, St. Louis , MO), 1 mM PMSF, pH 7.25]. Cell lysate and 
fluorogenic substrates [aminomethylcoumarin-conjugated caspase-3- and caspase–8- specific 
peptides (Ac-DEVD-AMC for caspase-3 and Ac-VETD-AMC for caspase-8; Sigma- Aldrich, St. 
Louis, MO)] were mixed in caspase reaction buffer (for caspase-3: 100 mM HEPES, 10% 
sucrose, 5 mM dithiothreitol, 0,1% CHAPS pH 7.25; for caspase-8: 75 mM Na+ MOPS, 10% 
glycerol, 1 mM dithiothreitol, 0.25 mM EDTA pH 7.5). Aminomethylcoumarine (AMC) liberation 
was detected after 1 h incubation at 37°C using a Fluoroskan Ascent FL plate reader (Thermo 
Scientific, Vantaa, Finland) with excitation at 355 nm and emission at 460 nm. 
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Internucleosomal DNA fragmentation was detected 4, 8, 16 h after UVA irradiation (2.5 J/cm2) 
by agarose gel electrophoresis as described previously [30]. 
 
1.11. [3H]-NAD Incorporation Assay 
 
The PARP activity assay was carried out as described previously [31].  
 
1.12. Immunofluorescent staining for PAR 
PAR polymer was detected by immunocytochemistry as described previously [26], except 
that fluorescence detection (AlexaFluor488-conjugated anti-mouse IgG antibody; Life 
Technologies, Budapest, Hungary) was used instead of peroxidase-labeled secondary 
antibody and nuclei were stained with TO-PRO-3 dye (Thermo Scientific, Vantaa, Finland). 
Samples were viewed and imaged with a Leica TCS SP8 confocal microscope. 
 
1.13. Spectroscopy 
Absorption spectrum of PJ-34 (dissolved in PBS) was measured with a Thermo Scientific 
Multiskan GO UV/VIS spectrophotometer. The NMR measurements were performed at 298 K 
on a Bruker AVANCE II spectrometer operating at 500.13 MHz proton resonance frequency. 
PJ34 (1 mg) was dissolved in 500 l DMSO-d6 in order to make all proton signals - including 
those of exchangeable NH- and OH-protons as well - detectable. 
 
1.14. Statistical analysis 
All experiments were performed at least three times on different days. All the values shown 
in the figures are expressed as mean±S.E.M. of n observations where n represents the number 
of observations. Intergroup comparisons involved one-way ANOVA followed by Tukey's test. 
A p-value less than 0.05 was considered as significant. 
 
2. Results 
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2.1. Silencing PARP-1 in A431 cells 
In order to investigate the role of PARP-1 in photochemotherapy, we chose A431 skin 
carcinoma cells (a common model cell line in PCT research [32]) and tried to silence PARP-1 
expression using siRNAs. The silencing efficiency of siRNAs in A431 cells was confirmed by 
a dual approach. On the one hand, we have detected PARP-1 protein levels by Western 
blotting, thus proving efficient gene silencing (Fig.1A). We have also used a functional test by 
treating cells with H2O2 in order to induce DNA breakage and detected poly(ADP-ribose) 
formation as a sign of PARP-1 activation. This latter approach also confirmed that our siRNA 
treatment was effective as PAR polymers could not be detected in H2O2-treated cells when 
PARP-1 was silenced (Fig.1B). 
 
2.2. PARP-1 is not a key regulator of PUVA-induced cytotoxicity 
Next, we determined the UVA sensitivity of A431 cells by irradiating them with different UVA 
doses (2.5–10 J/cm2) and determining the viability of cells at 16 h after irradiation (Fig. 2A). 
Based on these results, we chose the 2.5 J/cm2 UVA dose for subsequent experiments as it 
had no significant toxic effect on the cells (Fig. 2A) even after 48 h incubation (data not shown). 
In order to set up a photodynamic model we chose the photosensitizer compound 8-
methoxypsoralen (8-MOP) and pretreated the cells with the photosensitizer prior to irradiation 
with the non-toxic UVA dose (2.5 J/cm2). The combination of photosensitizer concentration 
and UVA dose was selected so that their combination cause a near 50% drop in viability in 
order to allow detection of further sensitization or protection by PARP-1 silencing (Fig. 2B). 
Interestingly, however, silencing PARP-1 had no significant effect on cell viability in this 
photochemotherapeutic cell death model. 
 
2.3. The PARP inhibitor PJ-34 acts as a photosensitizer  
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In order to further confirm that PARP-1 is not an important regulator of cell death in PUVA-
induced cytotoxicity, we also used two common PARP inhibitors PJ-34 and Veliparib. Cells 
were pretreated for 50min with PJ-34 (10 µM) or Veliparib (10 µM) followed by either the 
standard irradiation protocol with 2.5 J/cm2 UVA or (8-MOP treatment+UVA irradiation). 
Interestingly, PJ-34 (Fig. 2C) sensitized cells to UVA and also to UVA+8-MOP. It is noteworthy 
that the photosensitizing effect of PJ-34 was as potent as that of 8-MOP (Fig. 2C). In the dark 
control samples (cells kept in the dark without UVA radiation) PJ-34 had no toxic effect. In 
contrast to PJ-34, Veliparib a PARP inhibitor with comparable potency to PJ-34 (Fig. S1) had 
no such sensitizing effect to UVA (Fig. 2D). From the data obtained with the PARP-1 silenced 
A431 cells and those treated with Veliparib we concluded that PARP-1 is not a major player in 
PCT, but the PARP-1 independent photosensitizing effect of PJ-34 is worthy of investigation.  
 
2.4. The photosensitizing effect of PJ-34 can also be detected in spheroids 
In order to test whether or not the photosensitizing effect of PJ-34 is restricted to 2D 
cultures, we managed to grow spheroids from A431 cells and repeated the photosensitization 
experiments. We found that under special culture conditions (as detailed in the “Materials and 
Methods” section) A431 cells form spheroids (Fig. 3). PJ-34 sensitized cells to otherwise non-
toxic UVA doses, while the structurally unrelated Veliparib had no such effect (Fig. 3). The 
photosensitizing effect of PJ-34 in monolayers as well as in spheroids was also confirmed in 
an independent laboratory (Juarranz laboratory, Universidad Autónoma of Madrid; Fig. S2). 
 
2.5. The phototoxic effect of PJ-34 is not suppressed by antioxidants 
ROS are considered as central mediators of UVA toxicity [33]. Therefore, we have 
investigated whether or not PJ-34 augments ROS production and to what extent this may 
explain the photosensitizing effect of the compound. We detected ROS production using the 
ROS-sensitive fluorescent dye CM-H2DCFDA (Fig. 4) and in control experiments we ruled out 
false positive results caused by UVA-induced photooxidation of the probe. (Photooxidation 
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could be observed only at UVA doses higher than 20 J/cm2; data not shown). Moreover, we 
found that the antioxidants Trolox and ascorbic acid could not prevent phototoxicity of PJ-
34+UVA (Fig. 4A) despite efficiently scavenging UVA or PJ-34+UVA-induced ROS production 
(Fig. 4A, B). We have also tested the cytoprotective effects of additional antioxidants such as 
the cell-permeable antioxidant enzymes PEGylated-Catalase (PEG-CAT), PEGylated-
superoxide dismutase (PEG-SOD), glutathione (GSH), and gallotannin. These antioxidants 
either lacked any significant effect (PEG-CAT, GSH, gallotannin) or even sensitized cells 
further to PJ-34+UVA-induced cytotoxicity (PEG-SOD). Moreover, the fact that ROS 
production was significantly but not dramatically higher in PJ-34-UVA-treated cells compared 
to UVA-irradiated cells (Fig. 4B) may also raise the possibility that the photosensitizing effect 
of PJ-34 is not due to increased ROS production. However, definitive conclusions regarding 
the exact role of ROS species in this model cannot be drawn from data obtained with 
antioxidants and this issue may require further investigation. 
 
2.6. DNA damage accompanies the photogenotoxic effect of PJ-34 
In order to better understand the mechanism of the photosensitizing effects of PJ-34 in 
UVA-irradiated A431 cells, next we determined DNA damage in the irradiated cells. We found 
that at this subtoxic UVA dose no obvious sign of DNA strand breakage could be revealed with 
the alkaline single cell gel electrophoresis assay (comet assay) (Fig. 5A). However, in the 
presence of PJ-34, marked DNA breakage could be observed both immediately and 1 h after 
UVA treatment, which was absent in Veliparib-pretreated cells.  
Moreover, detection of phosphorylated H2AX histone variant (γH2AX) is a commonly used 
indicator of DNA damage triggered by photosensitizers [34]. We found γH2AX accumulation 
in PJ-34-pretreated and UVA-irradiated cells while the applied UVA dose alone or in 
combination with Veliparib had no such effect (Fig. 5B). In summary, of these two experiments 
it can be stated that DNA damage occurs in the presence of PJ-34 if cells are exposed to a 
subtoxic dose of UVA. In the timeframe, the investigated DNA damage proved stable. 
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2.7. UVA-irradiated A431 cells die by apoptosis in the presence of PJ-34 
In order to characterize the cell death induced by PJ-34+UVA treatment, apoptotic 
parameters were investigated. We found that 4 h after irradiation caspase-3, a central 
executioner of apoptosis is activated in UVA irradiated cells if PJ-34 is present (Fig. 6A), whilst 
Veliparib had no such effect. In the PJ-34+UVA-treated samples caspase activity was further 
enhanced at 8 h and the activity was sustained even 16 h after irradiation. Increased caspase-
3-like activity was also evidenced by detecting PARP-1 cleavage (PARP-1 was one of the first 
described substrates of caspase-3). The 89 kDa cleavage product of PARP-1 was detectable 
at 4 h after irradiation with its abundance increasing even further at 8 h and 16 h (Fig. 6B). 
Activation of caspase-8, an initiator caspase of the extrinsic apoptotic pathway could also be 
detected as early as 4 h after irradiation with further significant increases at 8 h and 16 h (Fig. 
6C). The active role of caspases in the cell death process initiated by PJ-34+UVA treatment is 
supported by our observations that the pan-caspase inhibitor z-vad-fmk, the caspase-3 
inhibitor z-DEVD-fmk as well as the caspase-8 inhibitor z-IETD-fmk protected A431 cells from 
the toxicity (Fig. 6D). In the course of apoptosis, effector caspases unleash the DNA 
fragmentation machinery. Internucleosomal DNA fragmentation could also be detected in our 
UVA irradiation model but only in the presence of PJ-34 and not in the presence of Veliparib 
(Fig. 7). A marked necrotic component could not be seen to accompany apoptosis.  
 
3. Discussion  
Although PDT and PCT differ in their applications as well as mechanism of action [3], both 
methods rely on the cytotoxic combination of a photosensitizer with light of matching 
wavelength [35]. While in PCT cellular events that are triggered by DNA damage which may 
induce secondary generation of reactive oxygen species, in PDT production of ROS is a 
primary event causing secondary oxidative DNA damage [5] as well as membrane damage 
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[36], activation of the immune system [37] [38], inhibition of cell proliferation [39] and 
vascularization [40].  
Current aims of PDT- and PCT-related research focus on improving equipment and the 
delivery of activating light, increasing the tumor specificity of the treatment and developing 
novel, more powerful sensitizer compounds [41]. The current paper investigates the potential 
role of PARylation in photosensitization which fits this latter trend. 
PARP-1 has already been implicated in the repair of UVC-induced DNA damage via the 
nucleotide excision repair (NER) pathway [42], its role in PUVA lesion repair has not yet been 
investigated. Thus, the primary aim of our study was to investigate the role of PARylation in 
the response of the cells to PUVA treatment. Our original hypothesis was that by inhibiting the 
repair of PUVA-induced DNA damage, PARP inhibition would sensitize cells to UVA light. 
Somewhat surprisingly, this hypothesis had to be rejected because both PARP-1 silencing and 
PARP inhibition by the specific and potent PARP inhibitor Veliparib (which is now in phase III 
clinical trial for the treatment of HER-2 negative breast cancer associated with BRCA mutations 
[43]) failed to sensitize cells to the toxic effects of PUVA or to low dose UVA radiation. The 
compound was not inactivated by the applied UV dose (Suppl. Fig S1), therefore, it seems that 
PARylation is not of vital importance for the repair of PUVA photoproducts and cannot be 
considered as a crucial survival mechanism in PUVA-treated cells.  
Interestingly, however, PJ-34 is a PARP inhibitor with similar or somewhat lower potency 
than Veliparib that did sensitize the cells to UVA both in 2D cultures and in spheroids. One 
peak in the absorption spectrum of PJ-34 overlaps with the emission spectrum of the UVA 
irradiator used in this study raising the possibility that the compound can absorb UVA light. 
Moreover, it appears likely that UVA irradiation triggers a structural change in the PJ-34 
molecule as indicated by the altered absorption spectrum and NMR spectrum of the compound 
recorded before and after UVA irradiation (Fig. S3). Based on the new resonance signals 
appearing in the aromatic (7-9 ppm) and phenolic -OH (11-11.5 ppm) regions, tautomers (ca. 
20-30% of PJ-34) with extended conjugated pi-electron system are likely to be formed (Fig. 
S3C). 
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The fact that the sensitizing effect of PJ-34 could be observed both in 2D and in 3D 
cultures is important because 3D spheroid cultures represent a “microtumor” and this model 
has been used with increasing frequency to evaluate photosensitizing agents [44] as spheroids 
more closely model nutrient supply, oxygenation, pH inhomogeneities than traditional 2D 
cultures. Similar sensitivity of cells to PJ-34+UVA in 2D as well as in 3D cultures provides 
support for confirming this effect also in in vivo animal models. 
Further characterization of the effects of PJ-34 revealed that the compound slightly 
increases UVA-induced ROS production and dramatically enhances DNA damage. Somewhat 
surprisingly, the antioxidants trolox or ascorbic acid (and several other antioxidants) failed to 
prevent photosensitization by PJ-34 despite efficiently scavenging UVA-induced or PJ-
34+UVA-induced ROS production. It must be noted here, however, that the data in the 
literature on the effects of various antioxidants are rather controversial with reports on ascorbic 
acid or trolox (the antioxidants used in our study) ranging from protection, to lack of effect or 
even potentiation of PDT phototoxicity [45-48]. The key to understanding this controversy may 
lie in differences in the severity of the PDT/PCT model, the cell type, the concentration and 
cellular/subcellular penetration of the photosensitizer, concentration of the antioxidants and 
various other variables of the biological models used in these studies. 
Two types of regulated cell death pathways (apoptosis and necrosis) have been shown to 
be induced by the interaction of light and photosensitizers [49] [32]. PCT-induced DNA damage 
triggered apoptotic cell death characterized by caspase activation and internucleosomal DNA 
fragmentation [34]. As for the caspases, both caspase-3 and caspase-8 were activated in PJ-
34+UVA-treated cells. Activation of caspase 8 may indicate that PCT treatment activated the 
extrinsic apoptotic pathway (e.g., via FAS signaling). Previous reports [50] showing the 
involvement of this route in PCT may support this scenario [51]. Alternatively, caspase-8 
activity may also result from activation of the caspase-3-caspase-6 axis downstream of 
apoptosome formation [52] [53]. Which of these two options may be relevant and what the 
hierarchy of caspases is in our model, requires further investigation. No sign of necrosis could 
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be seen in our model, thus necrosis does not appear to be the major pathway of cell death in 
PJ-34-sensitized and UVA-irradiated A431 cells. 
As for the practical implications of our findings, it appears plausible to suggest that PJ-34 
may be worth investigating as a novel photosensitizer with potential applications in PDT or in 
PCT. However, several open questions remain to be answered before PJ-34 may enter the 
path of translation. Its photosensitization effect must be characterized in more detail and 
various different types of cancer cell lines should be tested for sensitivity to PJ-34+UVA 
treatment. Furthermore, the in vivo efficiency of the compound should also be verified. 
  
PARP-independent photosensitization by PJ-34 16
Acknowledgements 
 
This research was supported by the European Union and the State of Hungary, and co-
financed by the European Social Fund in the framework of TÁMOP 4.2.4.A/2-11/1-2012-0001 
‘National Excellence Program’. The direct costs of this study were supported by the Hungarian 
Science Research Fund to L.V. (OTKA K112336) and to C.H. (OTKA PD116845), by MINECO 
(FIS PI12/01253), and Comunidad de Madrid (S2010/BMD-2359) to A.J. 
 
 
Conflict of interest: Authors declare no conflict of interest. 
  
PARP-independent photosensitization by PJ-34 17
Legends of figures 
Figure 1. Silencing of PARP-1 by siRNA 
PARP-1 expression was suppressed in A431 cells by siRNA. (A) Efficiency of silencing was 
confirmed by Western-blot analysis using a PARP-1 specific antibody. (B) In order to 
functionally characterize the effect of silencing, the cells were treated with 1 mM hydrogen-
peroxide and PAR production was detected by immunoblotting (TR control: DharmaFECT 
transfection reagent without siRNA; siCTL: transfected with non-target control siRNA; siPARP-
1: transfected with PARP-1-specific siRNA). In both cases ß–actin was used as loading control. 
Intensity of the bands was quantified by densitometry. Star symbol represents a statistically 
significant (*p<0.05) difference between A431 control cells and PARP-1 silenced cells on panel 
A or between H2O2 unexposed and exposed cells on panel B. Hashtag symbol indicates 
statistically significant (#p<0.05) difference in PAR accumulation between siCTL+ H2O2 and 
siPARP-1 + H2O2. 
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Figure 2. PARP-1 is not a key regulator of PDT but PJ-34 acts as a photosensitizer 
independently of its PARP inhibitory effect (A) The hypothesized potentiating effect of 
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PARP-1 silencing to UVA was tested by comparing the effects of PARP-1 silencing (siPARP-
1) to non-target siRNA (siCTL) or transfection reagent only (TR). Viability of cells was 
measured 16 h after UVA irradiation (2.5 – 10 J/cm2) with MTT assay. (B) Phototoxic effect of 
8MOP+UVA (2.5 J/cm2) on PARP-1 silenced A431 cells was measured in MTT assay 16 h 
after irradiation. (C) Effect of PJ-34 on 8MOP+UVA-induced cell death and (D) 
photosensitizing effect of PJ-34 compared to another potent PARP inhibitor Veliparib were 
determined in MTT assay at 16 h after UVA irradiation (2.5 J/cm2). Data on panels represent 
mean±S.E. of three independent experiments. Star symbol represents statistically significant 
(*p<0.05) difference between dark control cells and 8MOP+UVA-treated cells (B) or phototoxic 
effect of PJ-34 and 8MOP (C and D). Hashtag symbol indicates statistically significant 
(#p<0.05) sensitization by PJ-34 compared to 8MOP+UVA (C) or UVA (D).  
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Figure 3. Chemical phototoxicity of PJ-34 in spheroid cultures 
A431 spheroids were either left in the dark or were irradiated with 2.5 J/cm2 UVA in the 
presence of two PARP inhibitors PJ-34 (10 µM) or Veliparib (10 µM). Diameters were 
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measured 16 h after irradiation. Scale bar is 200 µm. Data on panels represent mean±S.E. of 
three independent experiments. Star symbol represents statistically significant (*p<0.05) 
difference between dark control and UVA irradiated cells. Hashtag symbol indicates 
statistically significant (#p<0.05) difference between UVA-irradiated and PJ-34+UVA-treated 
cells. 
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Figure 4. Antioxidants do not prevent UVA+PJ-34 induced phototoxicity despite 
efficiently scavenging ROS 
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A431 cells were either left in the dark or irradiated with 2.5 J/cm2 UVA in the presence of two 
PARP inhibitors PJ-34 (10 µM) or Veliparib (10 µM). Cell viability was measured with MTT 
assay 16 h after irradiation. The effects of the antioxidants trolox (200 µM) or ascorbic acid 
(500 µM) were tested on the viability (A) at 16 h or ROS production (B) (immediately after UVA 
irradiation). Data on panels represent mean±S.E. of three independent experiments. Star 
symbol represents statistically significant (*p<0.05) difference between dark control and UVA-
irradiated cells. Hashtag indicates statistically significant (#p<0.05) difference between UVA-
irradiated and PJ-34+UVA-treated cells. Dollar symbol indicates statistically significant 
($p<0.05) effect of antioxidants. 
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Figure 5. PJ-34 + UVA causes DNA damage  
(A) DNA single strand breaks were detected in alkaline Comet assay in the dark control cells 
and immediately or 1 h after UVA irradiation in the presence or absence of PARP inhibitors 
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PJ-34 (10 µM) or Veliparib (10 µM). Values of olive tail moment were used for quantitative 
analysis of DNA damage. Original magnification was 63x. Scale bar is 25 µm. (B) DNA double 
strand breaks were assessed by detecting γ-H2AX in the dark control cells or at indicated times 
after UVA irradiation (2.5 J/cm2) in the presence or absence of PARP inhibitors PJ-34 or 
Veliparib (10 µM). Intensity of the bands was quantified by densitometry. Data on panels 
represent mean±S.E. of three independent experiments. Star symbol represents statistically 
significant (*p<0.05) difference between dark control and UVA irradiated cells. Hashtag symbol 
indicates statistically significant (#p<0.05) effect of PJ-34 compared to UVA-exposed samples.  
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Figure 6. Photogenotoxic effect of PJ-34 triggers apoptotic cell death.  
(A) Caspase-3 and (C) caspase-8 activities were measured in dark control cells or at indicated 
times after UVA irradiation (2.5 J/cm2 ) in the presence or absence of the PARP inhibitors PJ-
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34 (10 µM) or Veliparib (10 µM). (B) PARP-1 cleavage was detected by immunoblotting in dark 
control cells or after UVA irradiation in the presence or absence of the PARP inhibitors PJ-34 
or Veliparib (10 µM) at indicated time points. ß–actin was used as loading control. Intensities 
of the bands were quantified by densitometry. (D) Protective effect of caspase inhibitors on 
cell viability was measured with MTT assay 16h after UVA irradiation (2.5 J/cm2) in the 
presence or absence of PARP inhibitors PJ-34 or Veliparib (10 µM) or in dark control cells. 
Data on panels represent mean±S.E. of three independent experiments. Star symbol 
represents statistically significant (*p<0.05) difference between dark control and UVA 
irradiated cells. Hashtag symbol indicates statistically significant (#p<0.05) between UVA 
irradiated and UVA + PJ-34 treated cells.  
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Figure 7. PJ-34 + UVA treatment causes DNA fragmentation.  
DNA fragmentation was detected in dark control cells or after UVA irradiation (2.5 J/cm2) in the 
presence or absence of PARP inhibitors PJ-34 or Veliparib (10 µM). Intensities of the bands 
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were quantified by densitometry. Data in panels represent mean±S.E. of three independent 
experiments. Star symbol represents statistically significant (*p<0.05) difference between dark 
control and UVA irradiated cells. Hashtag symbol indicates statistically significant (#p< 0.05) 
increase in DNA fragmentation in the presence of PJ-34. 
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Supplementary Figure S1. PJ-34 and Veliparib are similarly potent PARP inhibitors and 
they do not lose their inhibitory ability upon UVA irradiation 
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(A) A431 cells were exposed to hydrogen-peroxide (1 mM) for 7 min and PARP activation was 
measured in the 3H-NAD-based PARP activity assay. (B and C) Hydrogen-peroxide- (1 mM) 
or UVA-induced PAR accumulation was detected by immunostaining and Western-blot 
analysis using a PAR-specific antibody. In the case of immunostainings (B) nuclei were 
counterstained with TO-PRO. Original magnification was 63x. Scale bar is 25 µm. On the 
immunoblots (C) ß–actin was used as a loading control and the intensity of the bands was 
quantified by densitometry. In all experiments, A431 cells were pretreated with two specific 
PARP inhibitors PJ-34 or Veliparib (in indicated concentrations) prior to the hydrogen-peroxide 
treatment or UVA irradiation (2.5 J/cm2). Data on panels represent mean±S.E. of three 
independent experiments. Star symbol represents statistically significant (*p<0.05) effect of 
hydrogen-peroxide treatment. Hashtag symbol indicates statistically significant (#p<0.05) 
effect of PARP inhibitors on hydrogen-peroxide-induced PARP activation (A) or PAR 
accumulation (C). 
 
Supplementary Figure S2. Confirmation of spheroid data 
Spheroid data presented in Figure 3 (produced in the Virag laboratory, Debrecen, Hungary) 
were confirmed by findings from an independent laboratory (i.e., that of Angeles Juarranz, 
Madrid, Spain).  
A. Cellular morphology of A-431 cells (monolayer and spheroids) analyzed by phase contrast 
at 16 h after treatments. B. Cell survival of A-431 cells (monolayer and spheroids) measured 
by MTT assay at 16 h after the different treatments. (**p<0,001) 
Method used to grow spheroids was different from the protocol used by the Virag laboratory. 
Here, 80% confluent cultures were harvested with trypsin and gently pipetted to form a single 
cell suspension. The cells were centrifuged at 1700 rpm for 5 min, resuspended in spheroid 
medium and plated in appropriated plates. Parallel control cultures were seeded in spheroid 
medium and grown as attached monolayers on conventional plastic plates. The spheroid 
medium consists of DMEM/F12 (1:1) (HyClone, Logan, Utah/Gibco, Waltham, Massachusetts) 
containing 2% B27 serum-free supplement (Invitrogen, Frederick, Maryland), 20 ng/ml EGF, 
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0.4% bovine serum albumin and 4 μg/ml insulin (Sigma, St. Louis, Missouri). The cells were 
plated at 40,000 cells per 9.5 cm2 well in 1.2% poly-HEMA coated plates. Poly-HEMA was 
prepared by suspending 1.2 g poly-HEMA (Sigma, 2-hydroxyethyl methacrylate) per 100 ml 
95% ethanol and heating at 65°C with mixing. Dishes were coated by addition of 2.5 ml of poly-
HEMA stock per 9.5 cm2 dish in a sterile hood. The ethanol was evaporated overnight and the 
plates were sterilized by 1 h UV irradiation (Adhikary G et al. 2013; DOI: 
10.1371/journal.pone.008432). For treatments, both spheroids and attached monolayer 
cultures were treated for 1 h with 10 µM PJ-34, washed in PBS and subjected to UVA 
irradiation (2.5 J/cm2). Cultures were evaluated morphologically by phase contrast microscopy 
and by MTT for measuring cell survival after treatment (16 h). Scale bar is 100 µm.  
 
Supplementary Figure S3. UVA irradiation alters the absorption spectrum and the 1H 
NMR spectrum of PJ-34 
The absorption spectrum of PJ-34 solution (500 M in PBS) has been recorded with a UV/VIS 
spectrophotometer (A). The compound was dissolved in DMSO-d6 (1 mg/500 l) for NMR 
spectroscopy (B). UV and NMR spectra were recorded both before and after irradiation with 
2.5 J/cm2 UVA. Structure of PJ-34 as well as proposed structures of UVA-induced tautomers 
are shown (C). 
 
Supplementary Table S1 
A431 cells were pretreated for 30 min with the indicated concentrations of the listed 
antioxidants followed by PJ34+UVA treatment as described in the ‘Methods’ section. Viability 
was determined with the MTT method and cytoprotective effects were calculated and 
expressed as % protection. (Negative values indicate sensitizing rather than a protective 
effect.) Star symbol represents statistically significant (*p<0.05; **p<0.01) cytoprotective or 
sensitizing effects of the treatments. 
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